PHARMACOVIGILANCE: ENHANCING DRUG SAFETY MONITORING AND REPORTING SYSTEMS

Turki Matar Khalaf Alanzi; Bander Ibrahim Alomair; Obied Mathil Almotiry; Bader Seed bin owimer; Khaled Atteyah Abdullah alzahrani; Jabril Ali Mansour Dahhas; Khalid Thamer Alnofeai

doi:10.53555/jptcp.v29i04.5675

Turki Matar Khalaf Alanzi
Bander Ibrahim Alomair
Obied Mathil Almotiry
Bader Seed bin owimer
Khaled Atteyah Abdullah alzahrani
Jabril Ali Mansour Dahhas
Khalid Thamer Alnofeai

Keywords

pharmacovigilance, drug safety, monitoring, reporting, adverse drug reactions

Abstract

Pharmacovigilance plays a vital role in enhancing drug safety monitoring and reporting systems to ensure safe and effective use of medications. This essay highlights the importance of pharmacovigilance in improving drug safety, explores the methods used in monitoring and reporting adverse drug reactions, and discusses the results of implementing pharmacovigilance systems. The essay also delves into the challenges and future perspectives of pharmacovigilance. By focusing on enhancing drug safety monitoring and reporting systems through pharmacovigilance, healthcare professionals can better identify and manage adverse drug reactions, ultimately improving patient outcomes and public health.

Abstract 64 | PDF Downloads 25

References

1. World Health Organization. The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/ pharmvigi/en/. Accessed October 10, 2021.
2. Uppsala Monitoring Centre. What is Pharmacovigilance? https://www.who-umc.org/pharmacovigilance/what-is-pharmacovigilance/. Accessed October 10, 2021.
3. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
4. Arimone Y, Bidault I, Dutertre JP et al. Analysis of under-reporting of ADRs in France. Pharmacoepidemiol Drug Saf. 2015;24(4):400-407.
5. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - Module I - Pharmacovigilance systems and their quality systems. https://www.ema.europa.eu/en/ documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf. Accessed October 10, 2021.
6. MedDRA. Medical Dictionary for Regulatory Activities (MedDRA) - Introductory Guide Version 24.1. https://www.meddra.org/sites/default/files/guidance/file/intguide_24.1_English .pdf. Accessed October 10, 2021.
7. Hazell L, Kress HG. The early detection of drugs adverse effects: a review of the possibilities and limitations of spontaneous reports data. Drug Saf. 2007;30(8):711-717.
8. Vandenbroucke JP. Registries and monitoring systems for drug safety: a necessary complement to clinical trials. Public Health. 2013;13:1043.
9. McGettigan P, Roderick P, Kadam A, Pollock AM. Access to data from clinical trials: the future in the EU. BMJ. 2017;357:j2350.
10. Hanley JA Pharmacovigance: Learning from multiple sources of data. Pharmacoepidemiol Drug Saf. 201726(1):3-4.

PDF

Published

Oct 27, 2022

DOI https://doi.org/10.53555/jptcp.v29i04.5675

How to Cite

Turki Matar Khalaf Alanzi, Bander Ibrahim Alomair, Obied Mathil Almotiry, Bader Seed bin owimer, Khaled Atteyah Abdullah alzahrani, Jabril Ali Mansour Dahhas, & Khalid Thamer Alnofeai. (2022). PHARMACOVIGILANCE: ENHANCING DRUG SAFETY MONITORING AND REPORTING SYSTEMS. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 2860–2862. https://doi.org/10.53555/jptcp.v29i04.5675

Issue

Vol. 29 No. 04 (2022): JPTCP

Section

Articles

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.

Author Biographies